Branford, Conn.-based BioXcel Therapeutics Inc. closed its IPO of 5,454,545 common shares at $11 per share with gross proceeds of about $60 million.
The underwriters have an option to buy up to an additional 818,181 shares.
The biopharmaceutical company started trading on the Nasdaq Capital Market under the ticker symbol BTAI on March 8.
Barclays Capital Inc., UBS Securities LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering.
Canaccord Genuity Inc. acted as lead manager, while H.C. Wainwright & Co. LLC acted as independent financial adviser for the offering.
